Investors call the data impressive and then go silent. That gap is a narrative problem, and it's fixable.
Biotech founders are rarely undersold on the science. They're undersold on what the science means.
You can walk an investor through the mechanism, the data, and the regulatory pathway. And they can still decide they lack conviction. The feedback comes back as interesting, and the follow-up never arrives.
That isn't a data problem, and adding slides won't close it.
Not whether the science works. Your data settled that before the meeting.
They're underwriting whether the category you're creating will exist. And whether you're the company that leads it. Most biotech decks answer neither, because they were built to prove the mechanism.
The same gap shows up commercially. Clinicians find the science compelling and still have no frame for where it fits. So adoption stays theoretical.
Medtech branding. A named category, framed scientifically and economically, and a narrative your whole company works from.
Investor and exit readiness. The narrative investors underwrite, and deck architecture built on the belief they must hold. Plus targeting that finds the funds whose thesis fits.
Commercial traction. Founder-led authority, search visibility, and KOL programs, once there's a category to teach.
Most biotech engagements start with the first two. Commercial execution matters later, and it matters less than founders expect before the narrative holds.
Our depth is medical devices and diagnostics. But the work transfers wherever the buyer is clinical or institutional.
Diagnostics, precision medicine, and platform biotechs are a good fit.
We're less useful if your motion runs through a pharma sales force. Same if your next milestone is a licensing deal rather than a market you have to build. We'll say so on the first call.
Omar Khateeb sold surgical robots into hospitals before he built an agency. He hosts State of MedTech, now past 400 episodes.
He speaks at the summits where life sciences funds gather. So the people you're trying to reach already know us.
MarketCraft is acknowledged in Market Engineering, published June 2026. Its author, Bruce Cleveland, ran product and marketing at Apple and Oracle, then became a founding partner at Wildcat Venture Partners. He named the gap where funded companies with real products stall.
"MarketCraft joined the board of investors meeting, they were very impressed by MarketCraft's results."
Lloyd Mencinger, CEO, Aqua Medical
No. Pre-revenue companies are underwritten almost entirely on narrative. It matters more now than it will later.
It shouldn't. Scientific audiences reject anything that overreaches, so everything we write ties a claim to its evidence.
Yes. We draft with claims constraints in view, and we build the review cycle into the calendar.
No. We work on category, narrative, and commercial positioning. Your medical writing team stays where it is.
Fixed scope for the foundational work, retainer for ongoing execution. You'll have both numbers on the first call.
We'll tell you which belief it fails to move. And that happens whether or not we work together.
Thirty minutes. And we won't bring one of our own.
P.S. The Pitch Deck Analyzer gives you a read in minutes, for nothing. Plenty of founders run it, fix what it finds, and never book a call.